AI Article Synopsis
- The Inspiris Resilia tissue valve has undergone extensive pre-clinical and clinical testing since its introduction in 2011, including large animal studies and multi-center evaluations in Europe and North America.
- The valve shows superior performance compared to traditional options like the Perimount valve, with ongoing studies since 2011 indicating no major complications and promising 5-year results without early degeneration.
- Designed for enhanced durability and reduced calcification, the valve allows for potential future procedures and is currently being evaluated in younger patients to assess its long-term benefits.
Article Abstract
Introduction: The Inspiris Resilia tissue valve was recently introduced into clinical practice. This review summarizes the pre-clinical and clinical studies leading to this new bioprosthesis.
Areas Covered: The novel Resilia tissue was tested extensively in a large animal model. The clinical use of the tissue started in 2011 with the European Feasibility study, followed by a North-American multi-center study. Since 2017, the Inspiris Resilia valve has been in full commercial use. Further prospective evaluations and registries are ongoing.
Expert Opinion: The Inspiris Resilia valve was clinically introduced after pre-clinical tests revealed superiority compared to contemporary therapy such as the Perimount valve. Prospective long-term follow-up studies on Resilia are ongoing since 2011 and reveal no major complications. Full 5-year data show no signs of early degeneration, but longer follow-up is certainly still needed. Several prospective registries are actively monitoring the outcome with the Inspiris Resilia valve now. The novel tissue, designed to mitigate calcification and increase durability, together with the expandable stent, facilitating potential future valve-in-valve (ViV) procedures, are the cutting-edge aspects. Clinical use in younger patients is currently ongoing: their follow-up and outcome will determine the added value of this valve.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/17434440.2021.1886921 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Successful surgical repair of aortic root rupture during transcatheter aortic valve implantation: a case report.
Gen Thorac Cardiovasc Surg Cases
October 2024
Department of Cardiovascular Surgery, Hakodate Municipal Hospital, 1-10-1 Minato-cho, Hakodate City, Hokkaido, 041-8680, Japan.
Background: Aortic root rupture is a rare but potentially fatal complication of transcatheter aortic valve implantation (TAVI). Herein, we report a case of aortic root rupture during TAVI that was successfully managed with partial aortic root repair and aortic valve replacement.
Case Presentation: An 83-year-old woman with severe bicuspid aortic stenosis underwent transfemoral TAVI using a 26 mm SAPIEN 3 Ultra RESILIA valve.
Pannus formation: a rare culprit of early bioprosthetic valve dysfunction-a case report.
Eur Heart J Case Rep
October 2024
Department of Cardiovascular Surgery, Kyushu University Hospital, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan.
Background: Early bioprosthetic valve dysfunction (BVD) due to pannus formation is uncommon in elderly patients, and only a limited number of cases have been reported.
Case Summary: An 84-year-old man presented with exertional dyspnoea 3 years after surgical aortic valve replacement (SAVR) with a 19 mm Epic™ valve (Abbott, Santa Clara, CA, USA). Transthoracic echocardiography demonstrated progressive BVD, and cardiac computed tomography (CT) revealed sub-aortic pannus formation.
Multicenter, propensity-weighted comparison of stented, rapid-deployment and new-generation aortic valves.
Int J Cardiol Heart Vasc
October 2024
Division of Cardiac Surgery, University of Padova, Padova, Italy.
Article Synopsis
- The study compares early clinical and hemodynamic outcomes of three types of bioprosthetic valves used in surgical aortic valve replacement: Magna Ease, Intuity, and Inspiris Resilia.
- Data from 2589 patients revealed that the Intuity valve had the shortest aortic cross clamp time, while Inspiris showed the lowest permanent pace-maker implantation rates.
- All devices demonstrated excellent outcomes, but Inspiris had the best overall performance with lower gradient measurements compared to the Magna Ease valve.
The Mitris RESILIA Valve: New Skin for a Proven Design.
Surg Technol Int
July 2024
European Hospital, UniCamillus-Saint Camillus International University of Health Sciences, Rome, Italy.
Article Synopsis
- The mitris valve combines features of two existing valves—the Carpentier-Edwards PERIMOUNT Magna Mitral Ease valve and INSPIRIS RESILIA tissue—for enhanced hemodynamic performance and durability.
- Its design includes a more flexible, saddle-shaped sewing cuff that fits the mitral valve better, reducing risks of complications during double-valve replacements.
- The valve also benefits from advanced technology that minimizes free aldehyde levels, suggesting improved long-term durability and reliability compared to earlier models.
Sex-related differences among patients undergoing surgical aortic valve replacement-a propensity score matched study.
Interdiscip Cardiovasc Thorac Surg
August 2024
Department of Cardiac Surgery, University Hospitals Leuven, Leuven, Belgium.
Article Synopsis
- The study aimed to explore differences in characteristics and 2-year outcomes after surgical aortic valve replacement (SAVR) between males and females, using data from two registries involving 933 patients.
- Females had certain clinical differences such as lower body mass index, higher surgical risk scores, and smaller valves compared to males, but these disparities largely disappeared after adjusting for similar baseline characteristics.
- Ultimately, despite a higher initial surgical risk profile, both sexes had comparable outcomes 2 years post-SAVR, indicating no significant differences in overall results based on sex.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!